|
As
of September 30, 2023, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
50,000 |
|
| Shares from the conversion of Series A Stock inclusive
of cumulative dividends |
|
|
246,544 |
|
| Shares from the conversion
of Series B Preferred Stock inclusive of dividends (1) |
|
|
363,485 |
|
| |
|
|
837,844 |
|
| (1) |
Pursuant
to agreements signed in October 2023 with the Series B Stockholders, upon a listing of the Company’s stock on Nasdaq or the
signing of an agreement to sell or merger the Company, these stockholders will automatically exchange all of their shares of
Series B Stock including accrued dividends through September 30, 2023 for a total of 642,018
shares of common stock (see Note 10 – Subsequent Events). |
As
of September 30, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
242,639 |
|
| Shares from the conversion of convertible notes and accrued interest |
|
|
79,727 |
|
| Shares from the conversion of Series A Stock inclusive of cumulative dividends |
|
|
111,563 |
|
| Shares from the conversion of Series B Preferred Stock inclusive of dividends |
|
|
271,490 |
|
| |
|
|
883,234 |
|
|